Ganciclovir for Cytomegalovirus: a Call for Indefinite Prophylaxis in Lung Transplantation

Journal of Heart and Lung Transplantation

Volumn 27, Issue 8, 2008, Pages 875-881

  Valentine, Vincent G ^a   Weill, David ^b   Gupta, Meera R ^a   Raper, Brad ^c   LaPlace, Stephanie G ^c   Lombard, Gisele A ^a   Bonvillain, Ryan W ^d   Taylor, David E ^c   Dhillon, Gundeep S ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OCHSNER MEDICAL CENTER   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH HAZARD; HUMAN; INCIDENCE; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BRONCHIOLITIS OBLITERANS; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMONIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 47649124261     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.05.009     Document Type: Article

References (31)

1. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 (1998) 1741-1751
2. Duncan S.R., Paradis I.L., Yousem S.A., et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 146 (1992) 1419-1425
3. Valentine V.G., Taylor D.E., Dhillon G.S., et al. Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant 21 (2002) 319-326
4. Valentine V.G., Robbins R.C., Berry G.J., et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 15 (1996) 371-383
5. Hopkins P.M., Aboyoun C.L., Chhajed P.N., et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 170 (2004) 1022-1026
6. Soghikian M.V., Valentine V.G., Berry G.J., et al. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 15 (1996) 881-887
7. Opelz G., Dohler B., and Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 (2004) 928-936
8. Duncan S.R., Grgurich W.F., Iacono A.T., et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 150 (1994) 146-152
9. Zamora M.R. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis 3 suppl 2 (2001) 49-56
10. Weill D., Lock B.J., Wewers D.L., et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 3 (2003) 492-496
11. Ruttmann E., Geltner C., Bucher B., et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81 (2006) 1415-1420
12. Zamora M.R., Nicolls M.R., Hodges T.N., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 4 (2004) 1635-1642
13. Humar A., Kumar D., Preiksaitis J., et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 5 (2005) 1462-1468
14. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 15 (1996) 1-15
15. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 12 (1993) 713-716
16. Palmer S.M., Grinnan D.C., Diane Reams B., et al. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 18 (2004) 179-185
17. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 12 (1999) 286-297
18. Bhorade S.M., Lurain N.S., Jordan A., et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 21 (2002) 1274-1282
19. McGavin J.K., and Goa K.L. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61 (2001) 1153-1183
20. Boivin G., Erice A., Crane D.D., Dunn D.L., and Balfour Jr. H.H. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 168 (1993) 332-335
21. Tikkanen J.M., Krebs R., Bruggeman C., Lemstrom K.B., and Koskinen P.K. Platelet-derived growth factor regulates cytomegalovirus infection-enhanced obliterative bronchiolitis in rat tracheal allografts. Transplantation 77 (2004) 655-658
22. Tikkanen J.M., Koskinen P.K., and Lemstrom K.B. Role of endogenous endothelin-1 in transplant obliterative airway disease in the rat. Am J Transplant 4 (2004) 713-720
23. Tikkanen J.M., Kallio E.A., Bruggeman C.A., Koskinen P.K., and Lemstrom K.B. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med 164 (2001) 672-679
24. Lemstrom K.B., Bruning J.H., Bruggeman C.A., et al. Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation 90 (1994) 1969-1978
25. Koskinen P.K., Nieminen M.S., Krogerus L.A., et al. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant 12 (1993) 724-729
26. Kroshus T.J., Kshettry V.R., Savik K., et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 114 (1997) 195-202
27. Tamm M., Aboyoun C.L., Chhajed P.N., et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 170 (2004) 1120-1123
28. Scott J.P., Higenbottam T.W., Sharples L., et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation 51 (1991) 813-817
29. Ettinger N.A., Bailey T.C., Trulock E.P., et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 147 (1993) 1017-1023
30. Burke C.M., Glanville A.R., Macoviak J.A., et al. The spectrum of cytomegalovirus infection following human heart-lung transplantation. J Heart Transplant 5 (1986) 267-272
31. Perreas K.G., McNeil K., Charman S., et al. Extended ganciclovir prophylaxis in lung transplantation. J Heart Lung Transplant 24 (2005) 583-587